Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong

Nat Commun. 2022 Jan 20;13(1):411. doi: 10.1038/s41467-022-28068-3.

Abstract

Prior research using electronic health records for Covid-19 vaccine safety monitoring typically focuses on specific disease groups and excludes individuals with multimorbidity, defined as ≥2 chronic conditions. We examine the potential additional risk of adverse events 28 days after the first dose of CoronaVac or Comirnaty imposed by multimorbidity. Using a territory-wide public healthcare database with population-based vaccination records in Hong Kong, we analyze a retrospective cohort of patients with chronic conditions. Thirty adverse events of special interest according to the World Health Organization are examined. In total, 883,416 patients are included and 2,807 (0.3%) develop adverse events. Results suggest vaccinated patients have lower risks of adverse events than unvaccinated individuals, multimorbidity is associated with increased risks regardless of vaccination, and the association of vaccination with adverse events is not modified by multimorbidity. To conclude, we find no evidence that multimorbidity imposes extra risks of adverse events following Covid-19 vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • COVID-19 / epidemiology
  • COVID-19 / immunology*
  • COVID-19 / virology
  • COVID-19 Vaccines / administration & dosage
  • COVID-19 Vaccines / adverse effects
  • COVID-19 Vaccines / immunology*
  • Databases, Factual / statistics & numerical data
  • Epidemics / prevention & control
  • Female
  • Hong Kong / epidemiology
  • Humans
  • Male
  • Middle Aged
  • Multimorbidity
  • Public Health / statistics & numerical data
  • Retrospective Studies
  • Risk Factors
  • SARS-CoV-2 / immunology*
  • SARS-CoV-2 / physiology
  • Vaccination / adverse effects
  • Vaccination / statistics & numerical data*

Substances

  • COVID-19 Vaccines